Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2023 07:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid...
May 10, 2023 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update

FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design...
May 03, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery...
April 18, 2023 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID

BEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...
March 15, 2023 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting...
March 08, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023

BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular...
March 02, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its...
January 30, 2023 16:01 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes Prioritization on Building External Partnerships and an Internal Pipeline Centered...
January 23, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023

BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...
January 12, 2023 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids

BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids...